Beacon Biosignals

Beacon Biosignals is a Boston-based private company founded in 2019 that operates at the intersection of AI, digital health, and clinical neuroscience. Its core technology platform uses sleep EEG as a stable window into central nervous system function, applying machine learning models trained on over 200,000 hours of data to generate pharmacodynamic biomarkers for drug developers. The company provides a full-service solution for clinical trials, from data capture to analysis, aiming to improve trial optimization, patient stratification, and labeling claims for its pharmaceutical partners. Beacon is trusted by leading life science companies and is positioned to transform precision neuroscience in drug development.

End-to-end platform combining an FDA-cleared at-home sleep EEG headband, AI/ML analytics software trained on 200,000+ hours of EEG data, and full-service clinical trial operations to generate quantitative biomarkers for CNS drug development.

Competitors include other digital biomarker companies (e.g., Winterlight Labs for speech, Altoida for digital motor biomarkers), traditional EEG analysis service providers, and large CROs developing internal capabilities. Beacon's differentiated focus on sleep EEG, its large proprietary dataset, and its integrated hardware/software/service platform are key competitive advantages.